MedTrace Logo

Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)

NCT01106287 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2016-02-04

Study results available
· View outcomes & findings →

Summary

This study will evaluate the safety and tolerability of single doses of MK-0941 based on assessment of clinical and laboratory adverse experiences

Conditions

Interventions

DRUG

MK-0941

A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period

DRUG

Comparator: Placebo

a single oral placebo will be administered in the designated period (Periods 1-5)

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2010-01-31
Completion
2010-03-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01106287 on ClinicalTrials.gov